# A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)

> **NCT00642460** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 112 (actual)

## Conditions studied

- Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** tocilizumab [RoActemra/Actemra]
- **DRUG:** Placebo
- **DRUG:** Non-steroidal anti-inflammatory drugs (NSAIDs)
- **DRUG:** methotrexate
- **DRUG:** corticosteroids

## Key facts

- **NCT ID:** NCT00642460
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-09
- **Final completion:** 2014-08
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2016-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00642460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00642460, "A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00642460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*